Loading...
A108 USTEKINUMAB IS EFFECTIVE FOR INDUCING CLINICAL, ENDOSCOPIC, AND RADIOGRAPHIC RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY
BACKGROUND: Ustekinumab is a monoclonal antibody targeting the p40 subunit of interleukins 12 and 23. Gastroenterologists have begun to prescribe ustekinumab off-label for treatment of Crohn’s disease (CD) due to promising clinical trials but robust open label data is lacking AIMS: Assess the real-w...
Na minha lista:
| Udgivet i: | J Can Assoc Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507693/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.109 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|